ProfileGDS5678 / 1428686_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 30% 30% 29% 29% 29% 29% 29% 29% 29% 30% 29% 29% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7200830
GSM967853U87-EV human glioblastoma xenograft - Control 22.6754630
GSM967854U87-EV human glioblastoma xenograft - Control 32.6795930
GSM967855U87-EV human glioblastoma xenograft - Control 42.6129629
GSM967856U87-EV human glioblastoma xenograft - Control 52.6212929
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7319529
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7126329
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6543129
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6311829
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6563729
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6618630
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6369629
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6703429
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6670830